Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
Nexgel Inc (NXGL) specializes in advanced hydrogel solutions for medical, cosmetic, and diagnostic applications through proprietary electron beam cross-linking technology. This page provides centralized access to official corporate announcements and strategic developments.
Investors and industry professionals will find verified updates including earnings reports, product launch details, regulatory milestones, and partnership announcements. Our curated news collection enables efficient tracking of NXGL's innovations in transdermal drug delivery systems and FDA-approved wound care solutions.
Key content categories include:
- Financial performance updates and SEC filings
- New hydrogel product releases across medical and consumer markets
- Manufacturing process innovations and patent developments
- Strategic collaborations in healthcare and cosmetics sectors
Bookmark this page for real-time access to NXGL's corporate communications and market-moving announcements. For comprehensive analysis of hydrogel industry trends, visit Stock Titan's research portal regularly.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, has announced a $950,000 registered direct offering at $2.30 per share, issuing 413,044 shares of common stock. The company is also conducting a concurrent private placement of unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25 per share.
The warrants will be exercisable immediately upon issuance with a five-year term. This financing, combined with their current cash position and a recent $1 million non-dilutive advance from STADA, aims to strengthen NEXGEL's balance sheet as they prepare for anticipated growth in the second half of the year. Alere Financial Partners, LLC served as the exclusive placement agent for the offering.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC hydrogel products, announced its CEO Adam Levy will participate in the 6th Annual CEO Networking Event hosted by Semco Capital. The event will take place on June 2, 2025 in Chicago, featuring a fireside chat with Scott Weis.
The networking event brings together microcap companies with strong management teams and growth potential. Interested investors can contact Scott Weis for attendance information.
NEXGEL (NASDAQ:NXGL), a hydrogel products manufacturer, has expanded its partnership with STADA Arzneimittel AG for the North American market. The collaboration focuses on launching digestive enzyme formulas and solutions for scars and stretch marks.
As part of this strategic expansion, STADA will provide $1 million in non-dilutive capital to support NEXGEL's product launches and marketing initiatives. The partnership aims to bring innovative health solutions to North American consumers, leveraging NEXGEL's expertise in high-water-content hydrogel products and STADA's position as a European consumer health leader.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone (U.S. Toll Free: 1-800-343-4849 or International: 1-203-518-9848) or webcast. A replay will be available through May 27, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with code 11159118. The webcast recording will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a specialist in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, has announced its participation in the upcoming Planet MicroCap Showcase: Vegas 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Wednesday, April 23, 2025, at 9:30 a.m. PT in Track 4 - Loire at the Paris Hotel & Casino, Las Vegas. The event runs from April 22-24, 2025.
Investors interested in one-on-one meetings with Mr. Levy can arrange appointments through Planet Micro representatives or by contacting KCSA Strategic Communications at NEXGEL@KCSA.Com. A webcast of the presentation will be available through the company's investor relations website.
NEXGEL (NASDAQ: NXGL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $3.04 million, up 181% year-over-year, while full-year revenue hit $8.69 million, increasing 112% compared to 2023.
Key Q4 metrics include gross profit of $1.13 million (37.2% margin) and net loss of $0.85 million. Full-year 2024 showed gross profit of $2.75 million (31.6% margin) with a net loss of $3.28 million. The company achieved over 100% revenue growth for the third consecutive year.
Notable developments include first shipments of SilverSeal® to Cintas, successful growth of the Silly George brand from $2M to $5M+ annual revenue, and partnership with STADA to launch Histasolv in North America. The company projects 2025 revenue guidance of $13 million and expects to achieve positive EBITDA during the year.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 24, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone at 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International). A replay will be available through April 3, 2025, accessible at 1-844-512-3921 (U.S.) or 1-412-317-6671 (International) using code 11158402. A webcast replay will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Tuesday, March 25th, 2025, at 9:30 a.m. ET. The two-day conference will take place on March 25-26, 2025, and interested parties can access the webcast through the provided link.
Investors seeking one-on-one meetings with Mr. Levy can arrange appointments through iAccess representatives or by contacting KCSA Strategic Communications.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and over-the-counter products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming Webull Consumer Virtual Webinar. The company's Chief Executive Officer, Adam Levy, will deliver a presentation on February 18, 2025, at 2:40 p.m. ET.
Investors interested in attending can access the webinar through the provided Webull zoom registration link. For those seeking one-on-one meetings with CEO Adam Levy, arrangements can be made through Webull representatives or by contacting KCSA Strategic Communications via email at NEXGEL@KCSA.Com.
FAQ
What is the current stock price of Nexgel (NXGL)?
What is the market cap of Nexgel (NXGL)?
